CHRA yields 33.56% · PFE yields 6.13%● Live data
📍 PFE pulled ahead of the other in Year 9
Combined, CHRA + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CHRA + PFE for your $10,000?
Charah Solutions, Inc. provides environmental services to the power generation industry in the United States. The company offers remediation and compliance services, including environmental management of landfills for coal-fired power generation facilities and new and existing ash ponds; and active pond management services, such as closure by removal, cap-in-place, and design and construction of new ponds. Its remediation and compliance services also include landfill development, construction, and management; site evaluation and characterization; preliminary design and cost estimates with life-cycle analysis; hydrogeological assessment; groundwater and containment modeling; permit application and processing for expansions and greenfield sites; design engineering; construction of landfills and cap and cover systems; conversion of impoundments to landfill sites; quality assurance and control, and documentation; engineered fills (off-site); and other related services. In addition, the company recycles recurring and contracted volumes of coal-fired power generation waste byproducts comprising bottom ash, fly ash, and gypsum byproducts for the use in various industrial purposes. Further, it provides coal ash management services; fossil services that include silo management, on-site ash transportation, and capture and disposal of ash byproduct from coal power operations; and manages combustion byproducts comprising bottom ash, as well as disposal of flue gas desulfurization gypsum, Pozatec/fixated scrubber sludge, and fluidized bed combustion fly ash; and environmental risk transfer services that manages the sites' remediation requirements. Charah Solutions, Inc. was founded in 1987 and is headquartered in Louisville, Kentucky.
Full CHRA Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.